On October 26, MSD announced its Q3 2023 earnings report, with third-quarter revenue of $15.962 billion, a year-over-year increase of 7%. The total revenue for the first three quarters was $45.485 billion.PD-1 InhibitorKeytruda Q3Sales: $6.3 billion (+17%), with a total revenue of 18.403 billion US dollars in the first three quarters. We will wait and see for this year's "blockbuster drug" competition with Semaglutide.Nine-valent HPV vaccineGardasil/Gardasil 9 Q3Sales reached $2.6 billion (+13%), with cumulative revenue for the first three quarters amounting to $7.015 billion, primarily driven by strong market demand in China.COVID-19 Oral MedicationLagevrio Q3Sales increased by 47% year-over-year, reaching $640 million, primarily driven by rising demand in Japan.In recent years,Keytruda andGardasil/GardKeytruda will continue to be the main driver of MSD's performance. MSD is also making every effort to continuously develop.KeytrudaThis super blockbuster.Combination chemotherapy, combination targeted therapy, and combination ADC will becomeKeytruda's Future Development Strategy. MSD has also invested heavily to establish several significant collaborations with domestic and international companies developing ADCs, including Kelun Botai and Daiichi Sankyo, thereby building a robust ADC pipeline.BesidesKeytruda, MSD in China this quarterThe FDA has granted Priority Review status to the application for sotatercept, a drug for pulmonary arterial hypertension.PDUFA Date: March 26, 2024; Oral PCSK9 Inhibitor MK-0616StartTwo Phase III clinical trials have been conducted to treat a broader population of hypercholesterolemia and patients with heterozygous familial hypercholesterolemia.TL1A Track Poised to Emerge as the Next Blockbuster in Autoimmune Field, MSD and Roche Compete for Positioning. This Quarter, MSDAcquired Prometheus Biosciences for $10.8 billionTL1A Antibody MK-7240 Initiates Phase III Clinical Trial for Ulcerative Colitis Treatment. Just a few days ago,Roche also invested$7.25 billionAcquired Telavant, Gaining a TL1A AntibodyRVT-3101Rights for R&D, production, and commercialization in the United States and Japan (see:$7.25 Billion! Roche Acquires Telavant, Gains a TL1A Antibody）。
Thanks to strong performance in the first three quarters, MSD has adjusted its full-year sales guidance from the previous $58.6 billion-$59.6 billion to $59.7 billion-$60.2 billion.
Copyright © 2023 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.Online Live Streaming & Offline Salon
↑ Long pressScan the code, Schedule Live ↑
